REVESTIVE (teduglutide), synthetic GLP-2 analogue

GASTROENTEROLOGY - New medicinal product
Opinions on drugs - Posted on Jun 02 2015

Reason for request

Inclusion

Moderate improvement in the treatment of patients with short bowel syndrome who have been receiving parenteral nutrition for several months.

 

  • REVESTIVE has Marketing Authorisation in the treatment of short bowel syndrome in adults. Patients should be stable following a period of intestinal adaptation after surgery. 
  • Its efficacy versus placebo in reducing the volume of parenteral nutrition necessary was at least 20% after 24 weeks. The level of evidence of the demonstration of efficacy is low.
  • Despite the lack of long-term efficacy and safety data and taking into account its efficacy in reducing the need for parenteral nutrition, in the absence of a therapeutic alternative, REVESTIVE provides a moderate therapeutic benefit in the treatment of short bowel syndrome in patients who have been receiving parenteral nutrition for several months.

Clinical Benefit

Substantial

-


Clinical Added Value

moderate

-


Therapeutic use

-

Contact Us

Évaluation des médicaments